Member Info for Fadec92

Morning Num4 thanks for info!

Formulation issues however are preventing higher intravenous doses from being explored to establish MTD, and delaying the completion of toxicity studies. To resolve this formulation issue, Sareum has engaged and funded formulation specialists in the UK. This work is ongoing and, if successful, will be expected to enable the completion of preclinical studies during the second half of 2018.

Initial preclinical toxicity studies show good tolerance of the candidate drug at the predicted therapeutic dose, with no significant side effects being seen. Formulation issues however are preventing higher intravenous doses from being explored to establish MTD, and delaying the completion of toxicity studies. To resolve this formulation issue, Sareum has engaged and funded formulation specialists in the UK. This work is ongoing and, if successful, will be expected to enable the completion of preclinical studies during the second half of 2018.

This could be it!

Thanks Boss for me that's right!

I agree it's been from 0.7 to 1 for a long time maybe now it's time that people hold and time to move's up the trading range it certainly deserves it! The news is all excellent and I sure all we hoped for, and I've learnt a bit over 2 years of holding with listening to presentations and googling, my friend ask me how's the shares going, so I told him with excitement and detail what has been progressing here, he said have you made money, I said a little and he said that's a pity but i said it's unbelievable how well things are going and i don't think people understand what going on but are going to see this through as I'm very happy with the way it's going I know peeps have got their grumbles with the bod for not marketing or promoting but we all know what they are good at creating molecules so that's all it takes one day it will just take off and I'm going to be here to take advantage of that! ;/)

Sareum Holdings PLC 13 February 2018 The Company's drug discovery technology platform (SKIL� - Sareum Kinase Inhibitor Library) is being applied to generate drug research programmes against other kinase targets. Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, announces that it expects to release its interim results for the six months to 31 December 2017 in the first two weeks of March.

"The granting of this patent in Japan and China is a key step in securing the protection of the intellectual property for our TYK2 programme in all major markets and it enhances the value of this programme as we progress discussions with potential licensing partners."

Nicholas Glover summarising the empirical data is unequivocal and would what too aggressively expand! Supply chain agreement with Janssen to provide niraparib to complete phase 1b/2 study with CHk1 inhibitor SRA737, as mentioned earlier!

Nicholas Glover summarising the empirical data is unequivocal and would what too aggressively expand! Supply chain agreement with Janssen to provide niraparib to complete phase 1b/2 study with CHk1 inhibitor SRA737, as mentioned earlier!

Hi Chesh alls good how are you bud? This is a good one, been here a while and expect to see until good profits!

Maybe the Dr Udai Banerji the guy that's been studying the trials from the royal Marsden will be the main speaker so it would be good to hear from him!

I just bought some just too top up even though the market dosn''t seam to be bothered by the news!

Do we expect a milestone payment as one trial is going to be phase 2! "This trial consists of two phases, a safety-oriented Dose Escalation Phase 1 in unselected 'all-comer' patients and an efficacy-oriented Cohort Expansion Phase 2 in patients with genetically-defined tumours that harbour genomic alterations linked to increased replication stress and hypothesized to be more sensitive to Chk1 inhibition. Sierra will provide an update on the Dose Escalation Phase 1 portion today""

Was you expecting a PYC rise! lol

Yes it quite sad that people do this! lol!

Give it rest Formul1187 ffs!

Of a Milestone payment yet, should we get for this?

Niraparib even! https://www.tesarobio.com/en/pipeline/niraparib

Thoth was going to ask that question apart from the data looks like it's a good combo, ours is lung cancer and Naraparib is ovarian and breast cancer, so trying to create a complete coverage cancer drug!